157 related articles for article (PubMed ID: 11473961)
1. Continuous administration of gonadotrophin-releasing hormone agonist during the luteal phase in IVF.
Fujii S; Sato S; Fukui A; Kimura H; Kasai G; Saito Y
Hum Reprod; 2001 Aug; 16(8):1671-5. PubMed ID: 11473961
[TBL] [Abstract][Full Text] [Related]
2. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
[TBL] [Abstract][Full Text] [Related]
3. Impact of clomiphene citrate during ovarian stimulation on the luteal phase after GnRH agonist trigger.
Derksen L; Tournaye H; Stoop D; Van Vaerenbergh I; Bourgain C; Polyzos NP; Haentjens P; Blockeel C
Reprod Biomed Online; 2014 Mar; 28(3):359-68. PubMed ID: 24456700
[TBL] [Abstract][Full Text] [Related]
4. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY
Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
[TBL] [Abstract][Full Text] [Related]
5. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
Hohmann FP; Macklon NS; Fauser BC
J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
[TBL] [Abstract][Full Text] [Related]
6. GnRH agonist treatment of luteal phase deficiency in HCG-triggered IVF cycles: a matched case-control study.
Mendoza-Tesarik R; Mendoza N; López CC; Tesarik J
Reprod Biomed Online; 2019 Aug; 39(2):225-230. PubMed ID: 31178369
[TBL] [Abstract][Full Text] [Related]
7. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study.
Humaidan P; Ejdrup Bredkjaer H; Westergaard LG; Yding Andersen C
Fertil Steril; 2010 Feb; 93(3):847-54. PubMed ID: 19200959
[TBL] [Abstract][Full Text] [Related]
8. Effect of disruption versus continuation of gonadotrophin-releasing agonist after human chorionic gonadotrophin administration on corpus luteum function in patients undergoing ovulation induction for in-vitro fertilization.
Valbuena D; Pellicer A; Guanes PP; Remohí J; Simón C
Hum Reprod; 1997 Oct; 12(10):2118-22. PubMed ID: 9402265
[TBL] [Abstract][Full Text] [Related]
9. [A prospective, randomized controlled study comparing the effects of gonadotropin-releasing hormone agonist long and short protocols for in vitro fertilization].
Ye H; Huang G; Pei L
Zhonghua Fu Chan Ke Za Zhi; 2001 Apr; 36(4):222-5. PubMed ID: 11783366
[TBL] [Abstract][Full Text] [Related]
10. Combined administration of gonadotropin-releasing hormone agonist with human chorionic gonadotropin for final oocyte maturation in GnRH antagonist cycles for in vitro fertilization.
Kim CH; Ahn JW; You RM; Kim SH; Chae HD; Kang BM
J Reprod Med; 2014; 59(1-2):63-8. PubMed ID: 24597289
[TBL] [Abstract][Full Text] [Related]
11. Repeated GnRH agonist doses for luteal support: a proof of concept.
Wiser A; Klement AH; Shavit T; Berkovitz A; Koren RR; Gonen O; Amichay K; Shulman A
Reprod Biomed Online; 2019 Nov; 39(5):770-776. PubMed ID: 31628035
[TBL] [Abstract][Full Text] [Related]
12. Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist.
Ragni G; Vegetti W; Baroni E; Colombo M; Arnoldi M; Lombroso G; Crosignani PG
Hum Reprod; 2001 Nov; 16(11):2258-62. PubMed ID: 11679500
[TBL] [Abstract][Full Text] [Related]
13. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles.
Lin MH; Wu FS; Lee RK; Li SH; Lin SY; Hwu YM
Fertil Steril; 2013 Nov; 100(5):1296-302. PubMed ID: 23993928
[TBL] [Abstract][Full Text] [Related]
14. Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10,000 IU).
Gerris J; De Vits A; Joostens M; Van Royen E
Hum Reprod; 1995 Jan; 10(1):56-62. PubMed ID: 7745071
[TBL] [Abstract][Full Text] [Related]
15. Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS.
Lainas GT; Kolibianakis EM; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas TG; Tarlatzis BC
Hum Reprod; 2013 Jul; 28(7):1929-42. PubMed ID: 23624582
[TBL] [Abstract][Full Text] [Related]
16. Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial.
Engmann LL; Maslow BS; Kaye LA; Griffin DW; DiLuigi AJ; Schmidt DW; Grow DR; Nulsen JC; Benadiva CA
J Ovarian Res; 2019 Jan; 12(1):8. PubMed ID: 30684970
[TBL] [Abstract][Full Text] [Related]
17. A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization.
Barmat LI; Chantilis SJ; Hurst BS; Dickey RP
Fertil Steril; 2005 Feb; 83(2):321-30. PubMed ID: 15705369
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
Krause BT; Ohlinger R
Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):87-92. PubMed ID: 16377065
[TBL] [Abstract][Full Text] [Related]
19. The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women.
Westergaard LG; Erb K; Laursen S; Rasmussen PE; Rex S
Hum Reprod; 1996 Jun; 11(6):1209-13. PubMed ID: 8671425
[TBL] [Abstract][Full Text] [Related]
20. An artificially induced follicle stimulating hormone surge at the time of human chorionic gonadotrophin administration in controlled ovarian stimulation cycles has no effect on cumulus expansion, fertilization rate, embryo quality and implantation rate.
Vermeiden JP; Roseboom TJ; Goverde AJ; Suchartwatnachai C; Schoute E; Braat DD; Schats R
Hum Reprod; 1997 Jul; 12(7):1399-402. PubMed ID: 9262265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
